{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:11:13Z","timestamp":1790673073819,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-025-03947-z","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T12:49:28Z","timestamp":1740055768000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Efficacy and safety of dupilumab in chronic hand eczema: a systematic review"],"prefix":"10.1007","volume":"317","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-8383-2295","authenticated-orcid":false,"given":"Nicole","family":"Asamoah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4020-4532","authenticated-orcid":false,"given":"Miranda K.","family":"Branyiczky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Almuqrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fares","family":"Alkhayal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noor","family":"Sakka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3399-4200","authenticated-orcid":false,"given":"Dimitra","family":"Bednar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohannad","family":"Abu-Hilal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,20]]},"reference":[{"issue":"4","key":"3947_CR1","doi-asserted-by":"publisher","first-page":"CD004055","DOI":"10.1002\/14651858.CD004055.pub2","volume":"4","author":"WA Christoffers","year":"2019","unstructured":"Christoffers WA, Coenraads PJ, Svensson \u00c5 et al (2019) Interventions for hand eczema. Cochrane Database Syst Rev 4(4):CD004055 Published 2019 Apr 26. https:\/\/doi.org\/10.1002\/14651858.CD004055.pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"3947_CR2","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1177\/12034754231188325","volume":"27","author":"JSS Ho","year":"2023","unstructured":"Ho JSS, Molin S (2023) A review of existing and New Treatments for the Management of Hand Eczema. J Cutan Med Surg 27(5):493\u2013503. https:\/\/doi.org\/10.1177\/12034754231188325","journal-title":"J Cutan Med Surg"},{"issue":"3","key":"3947_CR3","doi-asserted-by":"publisher","first-page":"213","DOI":"10.4103\/0019-5154.131372","volume":"59","author":"US Agarwal","year":"2014","unstructured":"Agarwal US, Besarwal RK, Gupta R, Agarwal P, Napalia S (2014) Hand Eczema. Indian J Dermatol 59(3):213\u2013224. https:\/\/doi.org\/10.4103\/0019-5154.131372","journal-title":"Indian J Dermatol"},{"issue":"5","key":"3947_CR4","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/cod.14035","volume":"86","author":"JP Thyssen","year":"2022","unstructured":"Thyssen JP, Schuttelaar MLA, Alfonso JH et al (2022) Guidelines for diagnosis, prevention, and treatment of hand eczema. Contact Dermat 86(5):357\u2013378. https:\/\/doi.org\/10.1111\/cod.14035","journal-title":"Contact Dermat"},{"key":"3947_CR5","unstructured":"Health Canada. Product Information: TOCTINO 30\u00a0mg. Published [2024 February 28] (2024) July 8. https:\/\/health-products.canada.ca\/dpd-bdpp\/info.do?lang=en%26code=82322"},{"issue":"9","key":"3947_CR6","first-page":"532","volume":"43","author":"D D\u2019Ippolito","year":"2018","unstructured":"D\u2019Ippolito D, Pisano M (2018) Dupilumab (Dupixent). Pharm Ther 43(9):532\u2013535","journal-title":"Pharm Ther"},{"issue":"6","key":"3947_CR7","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1016\/j.jaad.2023.12.066","volume":"90","author":"EL Simpson","year":"2024","unstructured":"Simpson EL, Silverberg JI, Worm M et al (2024) Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis: results from a phase 3, randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 90(6):1190\u20131199. https:\/\/doi.org\/10.1016\/j.jaad.2023.12.066","journal-title":"J Am Acad Dermatol"},{"key":"3947_CR8","doi-asserted-by":"publisher","unstructured":"Voorberg AN, Kamphuis E, Christoffers WA, Schuttelaar MLA (2024) Efficacy and safety of dupilumab in patients with severe chronic hand eczema with inadequate response or intolerance to alitretinoin: a randomized, double-blind, placebo-controlled phase IIb proof-of-concept study [published correction appears in Br J Dermatol. 190(3):e24-e26. doi: 10.1093\/bjd\/ljad482] [published correction appears in Br J Dermatol. 2024;191(1):e1. https:\/\/doi.org\/10.1093\/bjd\/ljae157]. Br J Dermatol. 2023;189(4):400\u2013409. https:\/\/doi.org\/10.1093\/bjd\/ljad156","DOI":"10.1093\/bjd\/ljae157 10.1093\/bjd\/ljad156"},{"issue":"3","key":"3947_CR9","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1159\/000496481","volume":"235","author":"N Lee","year":"2019","unstructured":"Lee N, Chipalkatti N, Zancanaro P, Kachuk C, Dumont N, Rosmarin D (2019) A Retrospective Review of Dupilumab for Hand Dermatitis. Dermatology 235(3):187\u2013188. https:\/\/doi.org\/10.1159\/000496481","journal-title":"Dermatology"},{"issue":"4","key":"3947_CR10","doi-asserted-by":"publisher","first-page":"e557","DOI":"10.1111\/jdv.18805","volume":"37","author":"CM Olesen","year":"2023","unstructured":"Olesen CM, Y\u00fcksel YT, Zachariae C et al (2023) Treatment of chronic hand eczema with dupilumab-A retrospective follow-up study. J Eur Acad Dermatol Venereol 37(4):e557\u2013e559. https:\/\/doi.org\/10.1111\/jdv.18805","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"S1","key":"3947_CR11","doi-asserted-by":"publisher","first-page":"S55","DOI":"10.1089\/derm.2023.0220","volume":"35","author":"FJ Navarro-Trivi\u00f1o","year":"2024","unstructured":"Navarro-Trivi\u00f1o FJ, Gal\u00e1n-Guti\u00e9rrez M, Hita JC, Ruiz-Villaverde R, Dom\u00ednguez-Cruz J, Pereyra-Rodr\u00edguez JJ (2024) Real-world clinical experience of Dupilumab in the treatment of Chronic Palmo-Plantar Eczema in patients with moderate-severe atopic dermatitis: 52-Week Follow-Up. Dermatitis 35(S1):S55\u2013S61. https:\/\/doi.org\/10.1089\/derm.2023.0220","journal-title":"Dermatitis"},{"issue":"8","key":"3947_CR12","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1111\/1346-8138.14982","volume":"46","author":"JAF Oosterhaven","year":"2019","unstructured":"Oosterhaven JAF, Voorberg AN, Romeijn GLE, de Bruin-Weller MS, Schuttelaar MLA (2019) Effect of dupilumab on hand eczema in patients with atopic dermatitis: an observational study. J Dermatol 46(8):680\u2013685. https:\/\/doi.org\/10.1111\/1346-8138.14982","journal-title":"J Dermatol"},{"issue":"2","key":"3947_CR13","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/cod.14104","volume":"87","author":"AN Voorberg","year":"2022","unstructured":"Voorberg AN, Romeijn GLE, de Bruin-Weller MS, Schuttelaar MLA (2022) The long-term effect of dupilumab on chronic hand eczema in patients with moderate to severe atopic dermatitis-52 week results from the Dutch BioDay Registry. Contact Dermat 87(2):185\u2013191. https:\/\/doi.org\/10.1111\/cod.14104","journal-title":"Contact Dermat"},{"issue":"2","key":"3947_CR14","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1111\/cod.13693","volume":"84","author":"L Loman","year":"2021","unstructured":"Loman L, Diercks GFH, Schuttelaar MLA (2021) Three cases of non-atopic hyperkeratotic hand eczema treated with dupilumab. Contact Dermat 84(2):124\u2013127. https:\/\/doi.org\/10.1111\/cod.13693","journal-title":"Contact Dermat"},{"issue":"6","key":"3947_CR15","doi-asserted-by":"publisher","first-page":"877","DOI":"10.25259\/IJDVL_721_2022","volume":"89","author":"T Li","year":"2023","unstructured":"Li T, Li H, Zhang J (2023) Dupilumab use in non-atopic chronic hand eczema: two cases and a review of the literature. Indian J Dermatol Venereol Leprol 89(6):877\u2013879. https:\/\/doi.org\/10.25259\/IJDVL_721_2022","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"1","key":"3947_CR16","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jaad.2018.02.073","volume":"79","author":"MJ Zirwas","year":"2018","unstructured":"Zirwas MJ (2018) Dupilumab for hand eczema. J Am Acad Dermatol 79(1):167\u2013169. https:\/\/doi.org\/10.1016\/j.jaad.2018.02.073","journal-title":"J Am Acad Dermatol"},{"key":"3947_CR17","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.2147\/CCID.S383327","volume":"15","author":"L Deng","year":"2022","unstructured":"Deng L, Luo Y, An B, Su M, Sang H, Liu F (2022) Recalcitrant palmar-plantar atopic dermatitis successfully treated with Dupilumab: a Case Series. Clin Cosmet Investig Dermatol 15:2421\u20132426 Published 2022 Nov 10. https:\/\/doi.org\/10.2147\/CCID.S383327","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"5","key":"3947_CR18","doi-asserted-by":"publisher","first-page":"S126","DOI":"10.1016\/j.anai.2021.08.405","volume":"127","author":"A Betsock","year":"2021","unstructured":"Betsock A, Henao M, M306 (2021) Severe occupational hand dermatitis in a surgical resident successfully treated with dupilumab. Ann Allergy Asthma Immunol 127(5):S126\u2013S127","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"3947_CR19","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.jdcr.2020.02.010","volume":"6","author":"GA Zhu","year":"2020","unstructured":"Zhu GA, Honari G, Ko JM, Chiou AS, Chen JK (2020) Dupilumab for occupational irritant hand dermatitis in a nonatopic individual: a case report. JAAD Case Rep 6(4):296\u2013298 Published 2020 Mar 25. https:\/\/doi.org\/10.1016\/j.jdcr.2020.02.010","journal-title":"JAAD Case Rep"},{"issue":"7","key":"3947_CR20","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1111\/ijd.17098","volume":"63","author":"H Dong","year":"2024","unstructured":"Dong H, Chen W, Liang B, Li H (2024) Treatment of refractory hand eczema by dupilumab: a case report. Int J Dermatol 63(7):972\u2013974. https:\/\/doi.org\/10.1111\/ijd.17098","journal-title":"Int J Dermatol"},{"key":"3947_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/JAA.S399340","volume":"16","author":"Y Li","year":"2023","unstructured":"Li Y, Xiao J, Sun Y, Fang H, Qiao J (2023) Quick Treatment of Very Severe Refractory Hand and Foot Eczema with Dupilumab: a Case Report and Literature Review. J Asthma Allergy 16:1\u20138 Published 2023 Jan 5. https:\/\/doi.org\/10.2147\/JAA.S399340","journal-title":"J Asthma Allergy"},{"issue":"4","key":"3947_CR22","doi-asserted-by":"publisher","first-page":"484","DOI":"10.18502\/ijaai.v21i4.10296","volume":"21","author":"H Gan","year":"2022","unstructured":"Gan H, Gao YD (2022) Occupational Chronic Hand Dermatitis in Hospital Environment successfully treated with Dupilumab: a Case Report. Iran J Allergy Asthma Immunol 21(4):484\u2013487 Published 2022 Aug 12. https:\/\/doi.org\/10.18502\/ijaai.v21i4.10296","journal-title":"Iran J Allergy Asthma Immunol"},{"issue":"1","key":"3947_CR23","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/cod.13501","volume":"83","author":"AS Halling","year":"2020","unstructured":"Halling AS, Zachariae C, Thyssen JP (2020) Severe treatment-resistant acute and recurrent vesicular chronic hand eczema successfully treated with dupilumab. Contact Dermat 83(1):37\u201338. https:\/\/doi.org\/10.1111\/cod.13501","journal-title":"Contact Dermat"},{"issue":"8","key":"3947_CR24","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1001\/jamadermatol.2018.2027","volume":"154","author":"JAF Oosterhaven","year":"2018","unstructured":"Oosterhaven JAF, Romeijn GLE, Schuttelaar MLA (2018) Dupilumab Treatment of Very Severe Refractory Atopic Hand Eczema. JAMA Dermatol 154(8):969\u2013970. https:\/\/doi.org\/10.1001\/jamadermatol.2018.2027","journal-title":"JAMA Dermatol"},{"issue":"11","key":"3947_CR25","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1111\/ddg.13929","volume":"17","author":"AB Weins","year":"2019","unstructured":"Weins AB, Biedermann T, Eyerich K, Moeckel S, Schnopp C (2019) Successful treatment of recalcitrant dyshidrotic eczema with dupilumab in a child. J Dtsch Dermatol Ges 17(11):1165\u20131167. https:\/\/doi.org\/10.1111\/ddg.13929","journal-title":"J Dtsch Dermatol Ges"},{"issue":"2","key":"3947_CR26","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/cod.13266","volume":"81","author":"MN Crepy","year":"2019","unstructured":"Crepy MN, Nosbaum A, Bensefa-Colas L (2019) Blocking type 2 inflammation by dupilumab does not control classic (type 1-driven) allergic contact dermatitis in chronic hand eczema. Contact Dermat 81(2):145\u2013147. https:\/\/doi.org\/10.1111\/cod.13266","journal-title":"Contact Dermat"},{"issue":"7","key":"3947_CR27","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.3390\/jcm13071876","volume":"13","author":"C Paganini","year":"2024","unstructured":"Paganini C, Maffei V, Vellucci L et al (2024) Efficacy and safety of Dupilumab in the treatment of Hand Eczema: a retrospective study. J Clin Med 13(7):1876. https:\/\/doi.org\/10.3390\/jcm13071876. Published 2024 Mar 24","journal-title":"J Clin Med"},{"issue":"5","key":"3947_CR28","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1111\/cod.1465","volume":"91","author":"Y Bouderbala","year":"2024","unstructured":"Bouderbala Y, Quere I, Guillemard S, Dereure O, Raison-Peyron N (2024) Effectiveness of dupilumab on chronic lymphedema associated hand dermatitis. Contact Dermat 91(5):448\u2013450. https:\/\/doi.org\/10.1111\/cod.1465","journal-title":"Contact Dermat"},{"key":"3947_CR29","unstructured":"Efficacy and Safety of Dupilumab Chronic Hands Eczema Refractory to Highly Potent Topical Corticosteroids (DUPECZEMAIN), Identifier NCT 03861455. https:\/\/clinicaltrials.gov\/study\/NCT03861455?cond=Hand%20Dermatitis%26intr=Dupilumab%26rank=2. Accessed November 23, 2024"},{"key":"3947_CR30","unstructured":"Dupilumab in Severe Chronic Hand Eczema (DUPSHE), Identifier (2024) NCT04512339. https:\/\/clinicaltrials.gov\/study\/NCT04512339?cond=Hand%20Dermatitis%26intr=Dupilumab%26rank=1. Accessed November 23"},{"issue":"Suppl 1","key":"3947_CR31","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/jdv.16061","volume":"34","author":"T Agner","year":"2020","unstructured":"Agner T, Elsner P (2020) Hand Eczema: epidemiology, prognosis and prevention. J Eur Acad Dermatol Venereol 34(Suppl 1):4\u201312. https:\/\/doi.org\/10.1111\/jdv.16061","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"3947_CR32","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jaci.2018.08.022","volume":"143","author":"E Guttman-Yassky","year":"2019","unstructured":"Guttman-Yassky E, Bissonnette R, Ungar B et al (2019) Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol 143(1):155\u2013172. https:\/\/doi.org\/10.1016\/j.jaci.2018.08.022","journal-title":"J Allergy Clin Immunol"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-025-03947-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-025-03947-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-025-03947-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T12:49:30Z","timestamp":1740055770000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-025-03947-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,20]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3947"],"URL":"https:\/\/doi.org\/10.1007\/s00403-025-03947-z","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,20]]},"assertion":[{"value":"25 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"NA, MKB, NS, AA, FA, DB declare no conflicts of interest. MAB served as consultants and received honorarium from AbbVie, Biojamp, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, Galderma, Incyte, Janssen, Leo, Lilly, Medexus, Novartis, Pfizer, Recodrdati, Sanofi Regeneron, Sun Pharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"441"}}